Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective of this trial is to evaluate the activity of FK228 in patients with metastatic prostate cancer who have developed a rising PSA while undergoing hormonal therapy. Activity will be measured as the rate of disease control (complete response [CR], partial response [PR], or stable disease [SD] for at least 6 months).
Inclusion criteria
- metastatic prostate cancer